Economic consequences of molecular profiling for metastatic solid tumors. Cost-effectiveness of pazopanib (PAZ) versus sunitinib (SUN) as first-line treatment of metastatic renal cell carcinoma (mRCC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback